Year |
Title |
Altmetric |
2021
|
An enhanced recovery protocol decreases complication rates in high-risk gynecologic oncology patients undergoing non-emergent laparotomy.
International Journal of Gynecological Cancer.
31:647-655.
2021
|
|
2021
|
Standing on the shoulders of giants: Mentorship advice from leaders in the field.
Gynecologic Oncology.
161:339-341.
2021
|
|
2020
|
Decreasing opioid use in postoperative gynecologic oncology patients through a restrictive opioid prescribing algorithm.
Gynecologic Oncology.
159:773-777.
2020
|
|
2020
|
Niraparib maintenance in frontline management of ovarian cancer: A cost effectiveness analysis.
International Journal of Gynecological Cancer.
30:1569-1575.
2020
|
|
2020
|
The financial impact of an enhanced recovery after surgery (ERAS) protocol in an academic gynecologic oncology practice.
Gynecologic Oncology.
156:284-287.
2020
|
|
2019
|
Timing of robotic hysterectomy after cervical excisional procedure.
International Journal of Gynecological Cancer.
29:1110-1115.
2019
|
|
2019
|
Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Gynecologic Oncology.
153:381-384.
2019
|
|
2019
|
Options for assisted reproduction in young women with uterine cancer a cost-effectiveness analysis
2019
|
|
2018
|
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Cancer.
124:4657-4666.
2018
|
|
2018
|
Enhanced Recovery After Surgery in Surgical Specialties: Gynecologic Oncology.
Surgical Clinics of North America.
98:1275-1285.
2018
|
|
2018
|
Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.
Gynecologic Oncology.
151:282-286.
2018
|
|
2018
|
Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer..
Gynecologic Oncology.
151:4-5.
2018
|
|
2018
|
The impact of racial, geographic, and socioeconomic risk factors on the development of advanced-stage cervical cancer.
Journal of Lower Genital Tract Disease.
22:269-273.
2018
|
|
2018
|
Predictors of Unplanned Reoperation for Ovarian Cancer Patients from the National Surgical Quality Improvement Program Database.
International Journal of Gynecological Cancer.
28:1427-1431.
2018
|
|
2018
|
A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer
2018
|
|
2018
|
The challenge of HPV vaccination uptake and opportunities for solutions: Lessons learned from Alabama.
Preventive Medicine.
113:124-131.
2018
|
|
2018
|
High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women with Low-Grade Cervical Cytology.
Journal of Lower Genital Tract Disease.
22:207-211.
2018
|
|
2018
|
Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab
2018
|
|
2018
|
Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma.
Molecular Cancer Research.
16:813-824.
2018
|
|
2018
|
Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466.
Oncotarget.
9:19459-19459.
2018
|
|
2017
|
The evolution of and evidence for opportunistic salpingectomy.
Obstetrics and Gynecology.
130:814-824.
2017
|
|
2017
|
The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis.
Gynecologic Oncology.
146:642-646.
2017
|
|
2017
|
Preventing human papillomavirus–related cancers: we are all in this together.
American Journal of Obstetrics and Gynecology.
216:576.e1-576.e5.
2017
|
|
2017
|
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.
Gynecologic Oncology Reports.
20:81-86.
2017
|
|
2017
|
Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients?.
International Journal of Gynecological Cancer.
27:714-719.
2017
|
|
2017
|
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Oncotarget.
8:44159-44170.
2017
|
|
2016
|
Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service.
Gynecologic Oncology.
143:105-108.
2016
|
|
2016
|
Ovarian cancer and the immune system — The role of targeted therapies.
Gynecologic Oncology.
142:349-356.
2016
|
|
2016
|
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Gynecologic Oncology.
142:25-29.
2016
|
|
2016
|
Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Laboratory Investigation.
96:249-259.
2016
|
|
2016
|
Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?.
Gynecologic Oncology.
143:617-621.
2016
|
|
2016
|
Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancer.
Oncotarget.
7:86803-86815.
2016
|
|
2015
|
Niclosamide analogs for treatment of ovarian cancer.
International Journal of Gynecological Cancer.
25:1377-1385.
2015
|
|
2015
|
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
Gynecologic Oncology.
139:59-62.
2015
|
|
2015
|
Ovarian and cervical cancer patient derived xenografts: The past, present, and future.
Gynecologic Oncology.
138:486-491.
2015
|
|
2015
|
Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project.
International Journal of Gynecological Cancer.
25:798-801.
2015
|
|
2015
|
A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
Gynecologic Oncology.
136:293-299.
2015
|
|
2014
|
Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer.
International Journal of Gynecological Cancer.
24:1480-1485.
2014
|
|
2014
|
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
Journal of Nuclear Medicine.
55:1636-1642.
2014
|
|
2014
|
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?.
World Journal of Stem Cells.
6:441-447.
2014
|
|
2014
|
Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
2014
|
|
2014
|
Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients.
Gynecologic Oncology.
132:227-230.
2014
|
|
2014
|
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer.
Gynecologic Oncology.
134:112-120.
2014
|
|
2014
|
Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
Gynecologic Oncology.
132:203-210.
2014
|
|
2014
|
Outcomes of gynecologic oncology patients undergoing gastrografin small bowel follow-through studies.
2014
|
|
2014
|
Outcomes of gynecologic oncology patients undergoing robotic-assisted laparoscopic procedures in a university setting.
Journal of Robotic Surgery.
8:207-211.
2014
|
|
2014
|
Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.
Gynecologic Oncology.
133:142-146.
2014
|
|
2014
|
Validation of a venous thromboembolism risk assessment model in gynecologic oncology.
Gynecologic Oncology.
134:160-163.
2014
|
|
2013
|
The Wnt/β-catenin pathway in ovarian cancer: A review.
Gynecologic Oncology.
131:772-779.
2013
|
|
2013
|
Screening behaviors and cultural barriers in women with newly diagnosed cervical cancer..
Journal of Lower Genital Tract Disease.
17:425-429.
2013
|
|
2013
|
Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.
Gynecologic Oncology.
130:416-420.
2013
|
|
2013
|
Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Annals of Surgical Oncology.
20:3059-3065.
2013
|
|
2013
|
Perioperative morbidity and mortality in octogenarians with ovarian cancer.
International Journal of Gynecological Cancer.
23:1006-1009.
2013
|
|
2013
|
Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials.
Gynecologic Oncology.
129:251-257.
2013
|
|
2013
|
Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women
2013
|
|
2012
|
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.
Gynecologic Oncology.
127:420-425.
2012
|
|
2012
|
The utilization of palliative care in gynecologic oncology patients near the end of life..
Gynecologic Oncology.
127:175-179.
2012
|
|
2012
|
Management of complex pelvic masses using a multivariate index assay: A decision analysis.
Gynecologic Oncology.
126:364-368.
2012
|
|
2012
|
Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.
Gynecologic Oncology.
126:69-72.
2012
|
|
2012
|
The core competencies of James Marion Sims, MD..
Annals of Surgery.
256:193-202.
2012
|
|
2012
|
Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion.
Gynecologic Oncology.
125:646-648.
2012
|
|
2012
|
The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.
Gynecologic Oncology.
125:226-230.
2012
|
|
2012
|
The use of retinoids in ovarian cancer: A review of the literature.
International Journal of Gynecological Cancer.
22:191-198.
2012
|
|
2011
|
Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.
Gynecologic Oncology.
123:54-57.
2011
|
|
2011
|
A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma.
Gynecologic Oncology.
122:604-607.
2011
|
|
2011
|
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Gynecologic Oncology.
122:532-535.
2011
|
|
2011
|
Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy does preoperative anticoagulation matter?.
International Journal of Gynecological Cancer.
21:1131-1134.
2011
|
|
2011
|
The efficacy and toxicity of bevacizumab in combination with gemcitabine in patients with recurrent ovarian cancer.
Clinical Ovarian and other Gynecologic Cancer.
4:34-37.
2011
|
|
2011
|
Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Gynecologic Oncology.
121:193-199.
2011
|
|
2010
|
Overcoming TRAIL resistance in ovarian carcinoma.
Gynecologic Oncology.
119:157-163.
2010
|
|
2010
|
Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies.
International Journal of Gynecological Cancer.
20:103A.
2010
|
|
2010
|
Robotic surgery in gynecologic oncology fellowship programs in the USA: A survey of fellows and fellowship directors.
International Journal of Medical Robotics and Computer Assisted Surgery.
6:405-412.
2010
|
|
2010
|
The clinical impact of computed tomography immediately following primary chemotherapy in patients with epithelial ovarian cancer.
Clinical Ovarian and other Gynecologic Cancer.
3:52-55.
2010
|
|
2009
|
Life-space assessment in urogynecology and gynecological oncology surgery patients: A measure of perioperative mobility and function.
Journal of the American Geriatrics Society.
57:2263-2268.
2009
|
|
2009
|
Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients..
Obstetrics and Gynecology.
114:530-536.
2009
|
|
2009
|
The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study..
Gynecologic Oncology.
114:424-426.
2009
|
|
2009
|
The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Gynecologic Oncology.
114:242-245.
2009
|
|
2009
|
Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
International Journal of Gynecological Cancer.
19:814-819.
2009
|
|
2009
|
Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapy.
International Journal of Gynecological Cancer.
19:888-891.
2009
|
|
2009
|
The management of cervical intraepithelial neoplasia during pregnancy: Is colposcopy necessary?.
Journal of Lower Genital Tract Disease.
13:182-185.
2009
|
|
2009
|
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Gynecologic Oncology.
113:384-390.
2009
|
|
2009
|
In vitro chemoresponse assay results and population chemotherapy response rates in endometrial cancer..
Journal of Clinical Oncology.
27:5503.
2009
|
|
2009
|
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies..
Gynecologic Oncology.
112:601-604.
2009
|
|
2009
|
The effect of obesity on survival in patients with ovarian cancer.
Gynecologic Oncology.
112:389-393.
2009
|
|
2009
|
The role of comprehensive surgical staging in patients with endometrial cancer
2009
|
|
2008
|
Conservative Management of Postoperative Fever in Gynecologic Patients Undergoing Major Abdominal or Vaginal Operations.
Journal of the American College of Surgeons.
207:393-397.
2008
|
|
2008
|
Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.
Vaccine.
26:4314-4319.
2008
|
|
2008
|
Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model..
Journal of Clinical Oncology.
26:14695.
2008
|
|
2008
|
Lynch syndrome in women less than 50 years of age with endometrial cancer.
Obstetrics and Gynecology.
111:1161-1166.
2008
|
|
2008
|
Lipoxygenase pathway receptor expression in ovarian cancer.
Reproductive Sciences.
15:321-326.
2008
|
|
2008
|
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
Gynecologic Oncology.
108:591-597.
2008
|
|
2007
|
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma [15].
Obstetrics and Gynecology.
110:933-934.
2007
|
|
2007
|
Life Space Assessment in Urogynecology and Gynecologic Oncology Surgical Patients: A Functional Status and Health Analysis
2007
|
|
2007
|
Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: A retrospective university experience.
International Journal of Gynecological Cancer.
17:998-1002.
2007
|
|
2007
|
Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma - A cost-effectiveness analysis.
International Journal of Gynecological Cancer.
17:1019-1024.
2007
|
|
2007
|
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.
Gynecologic Oncology.
106:614-621.
2007
|
|
2007
|
Complete uterine necrosis following chemoradiation for advanced cervical cancer: A case report.
Gynecologic Oncology.
106:265-267.
2007
|
|
2007
|
Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multiinstitutional experience.
International Journal of Gynecological Cancer.
17:886-889.
2007
|
|
2007
|
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma.
Obstetrics and Gynecology.
109:1388-1395.
2007
|
|
2007
|
Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
Gynecologic Oncology.
105:291-298.
2007
|
|
2007
|
A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
Gynecologic Oncology.
105:223-227.
2007
|
|
2007
|
Diagnostic loop electrosurgical excisional procedure for discrepancy: Do preoperative factors predict presence of significant cervical intraepithelial neoplasia?.
Journal of Lower Genital Tract Disease.
11:69-72.
2007
|
|
2007
|
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer [13].
Obstetrics and Gynecology.
109:785.
2007
|
|
2006
|
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer.
Obstetrics and Gynecology.
108:1375-1379.
2006
|
|
2006
|
Cervical intraepithelial neoplasia in adolescent women: Incidence and treatment outcomes.
Obstetrics and Gynecology.
108:1369-1374.
2006
|
|
2006
|
Fertility sparing therapy in a patient with placental site trophoblastic tumor: A case report.
Gynecologic Oncology.
103:1141-1143.
2006
|
|
2006
|
Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision.
Gynecologic Oncology.
103:749-751.
2006
|
|
2006
|
Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based Chemotherapy.
Journal of the American College of Surgeons.
203:527-532.
2006
|
|
2006
|
Unilateral cervical cancer in a patient with cervix duplex.
Gynecologic Oncology.
103:346-348.
2006
|
|
2006
|
Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: A university teaching hospital experience.
International Journal of Gynecological Cancer.
16:1766-1769.
2006
|
|
2006
|
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
Gynecologic Oncology.
102:338-342.
2006
|
|
2006
|
Recurrent basosquamous cell carcinoma of the vulva.
Gynecologic Oncology.
102:400-402.
2006
|
|
2006
|
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Cancer.
107:536-543.
2006
|
|
2006
|
Use of complementary and alternative medicine and spiritual practices among women with ovarian carcinoma in the southeastern United States..
Journal of Clinical Oncology.
24:15048.
2006
|
|
2006
|
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Gynecologic Oncology.
101:46-54.
2006
|
|
2006
|
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients
2006
|
|
2006
|
Use of a fascial prosthesis for management of abdominal compartment syndrome secondary to obstetric hemorrhage.
Obstetrics and Gynecology.
107:493-496.
2006
|
|
2006
|
Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters).
Gynecologic Oncology.
100:219-220.
2006
|
|
2005
|
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base.
Gynecologic Oncology.
99:530-535.
2005
|
|
2005
|
A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses.
Gynecologic Oncology.
99:443-446.
2005
|
|
2005
|
Predictors of outcomes for women with cervical carcinoma.
Gynecologic Oncology.
99:432-436.
2005
|
|
2005
|
Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies..
Gynecologic Oncology.
98:490-492.
2005
|
|
2005
|
Management strategies for abnormal early pregnancy: A cost-effectiveness analysis
2005
|
|
2005
|
Feasibility of hand-assisted laparoscopic surgery (HALS) in gynecologic oncology patients..
Journal of Clinical Oncology.
23:5153.
2005
|
|
2005
|
A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia.
Obstetrical and Gynecological Survey.
60:96-97.
2005
|
|
2005
|
A prospective evaluation of "see and treat" in women with HSIL Pap smear results: Is this an appropriate strategy?.
Journal of Lower Genital Tract Disease.
9:2-6.
2005
|
|
2005
|
Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis.
Gynecologic Oncology.
97:387-394.
2005
|
|
2005
|
Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy.
Gynecologic Oncology.
97:713-715.
2005
|
|
2005
|
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy.
Gynecologic Oncology.
98:309-312.
2005
|
|
2004
|
Early abdominal incision recurrence in a patient with stage i adenocarcinoma of the endometrium.
Obstetrics and Gynecology.
104:1170-1172.
2004
|
|
2004
|
Some remarks on the somatic expression of sperm protein 17 [1] (multiple letters).
International Journal of Cancer.
111:972-973.
2004
|
|
2004
|
A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia.
Journal of Lower Genital Tract Disease.
8:280-284.
2004
|
|
2004
|
The impact of aborted radical hysterectomy in patients with cervical carcinoma.
Gynecologic Oncology.
95:204-207.
2004
|
|
2004
|
Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients..
Journal of Clinical Oncology.
22:5044.
2004
|
|
2004
|
Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy..
Journal of Clinical Oncology.
22:5083.
2004
|
|
2004
|
Expression of sperm protein 17 (Sp17) in ovarian cancer.
International Journal of Cancer.
108:805-811.
2004
|
|
2004
|
Immunohistochemical Evaluation of the c-kit Proto-oncogene in Sarcomas of the Uterus: A Case Series
2004
|
|
2004
|
The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy.
Gynecologic Oncology.
92:215-219.
2004
|
|
2003
|
A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3.
American Journal of Obstetrics and Gynecology.
188:1186-1188.
2003
|
|
2003
|
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation.
Gynecologic Oncology.
89:233-235.
2003
|
|
2003
|
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids.
Cancer Gene Therapy.
10:377-387.
2003
|
|
2003
|
Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy.
Gynecologic Oncology.
89:295-300.
2003
|
|
2003
|
Complications of indwelling venous access devices in patients with gynecologic malignancies.
Gynecologic Oncology.
91:591-595.
2003
|
|
2003
|
Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.
Gynecologic Oncology.
91:470-475.
2003
|
|
2002
|
Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture.
Obstetrics and Gynecology.
100:1061-1063.
2002
|
|
2002
|
Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture..
Obstetrics and Gynecology.
100:1061-1063.
2002
|
|
2002
|
Uterine leiomyosarcoma metastatic to the thyroid.
Obstetrics and Gynecology.
100:1122-1124.
2002
|
|
2002
|
Uterine leiomyosarcoma metastatic to the thyroid..
Obstetrics and Gynecology.
100:1122-1124.
2002
|
|
2002
|
A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis.
Gynecologic Oncology.
87:57-63.
2002
|
|
2002
|
Conservative management of Stage I endometrial carcinoma after surgical staging.
Gynecologic Oncology.
84:194-200.
2002
|
|
2001
|
Endometrial carcinoma.
Current Treatment Options in Oncology.
2:129-135.
2001
|
|
2001
|
Predictors of outcome in small cell carcinoma of the cervix - A case series.
Gynecologic Oncology.
83:216-220.
2001
|
|
2000
|
A patient presenting with a pelvic mass, elevated CA-125, and fever.
Gynecologic Oncology.
77:471-472.
2000
|
|